Introduction
Clinical and epidemiological studies have shown that breastfeeding has a protective effect on breast cancer risk. [1] [2] [3] Accumulating evidence has suggested that human breast milk may confer long-term benefits, such as reduced risks of certain autoimmune diseases, inflammatory bowel disease, and certain malignancies. Some studies have also indicated that a reduced incidence of breast cancer is the most well-documented long-term effect of breastfeeding on mothers; 4 however, the degree to which some of these health benefits may be realized depends on the breastfeeding duration, breastfeeding frequency, breastfeeding exclusivity, and other personal factors. 3 Efforts have been directed to identify the various immunoreactive substances in human breast milk that account for the protective effects of breastfeeding against diseases. [5] [6] [7] [8] However, additional studies must be conducted to elucidate the mechanisms involved in the protective effects of breastfeeding on reducing the risk of breast cancer. 2 Human breast milk is particularly rich in secretory IgA (SIgA) antibodies, [9] [10] [11] [12] [13] [14] which play a protective role against several diseases. These antibodies neutralize pathogens and simultaneously limit the damaging effects of tissue inflammation caused by other antibody types. 15 The biological activity of SIgA is important because this protein is the primary antibody class in human breast milk 12, 16 and because its activity can most likely be linked to the effect of breastfeeding on the reduced incidence of breast cancer.
Breast cancer therapy includes radiotherapy, chemotherapy, endocrine therapy, and biological agents, and treatments are increasingly being tailored to the individual tumor and patient to provide the maximum survival benefit with minor toxicity. 17 However, protein formulation development and protein integration into modified drug release systems are critical steps in developing proteins as therapeutic products. Proteinbased drugs, including antibodies, are being developed to attain better forms of therapy. The best formulation should be biocompatible, have minor toxicity, a good degree of tissuespecific action, and be easily prepared and administered and should not be cost-prohibitive. 18, 19 Polyethylene glycol (PEG) microspheres are polymeric particles that have the capacity to adsorb organic compounds and are considered a major drug carrier. 20 The adsorption capacity of microspheres for organic compounds can be modified to improve their biological function. 21 In a previous study, we showed that PEG microspheres are a promising agent for the delivery of amino acids, hormones, and medicinal plants because these microspheres can prevent the degradation of and increase the bioavailability of these substances within the organism, thus improving the immune function. [22] [23] [24] [25] [26] [27] [28] Nevertheless, no studies have linked SIgA adsorbed to PEG microspheres to the mechanisms of tumor cell growth; however, SIgA adsorbed to PEG microspheres may have an effect on breast tumor cells. The aim of this study was to investigate the effect of PEG microspheres with adsorbed SIgA on MCF-7 human breast cancer cells.
Materials and methods ethics
This study was approved by the Institutional Research Ethics Committee of the Campus of Araguaia of Federal University of Mato Grosso, Brazil (Protocol Number CAAE: 45102815.3.0000.5587) and all the subjects gave informed written consent for the use of their colostrum.
cell culture MCF-7 human breast cancer cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained as monolayer cultures in 75 cm 2 plastic culture flasks in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (Sigma-Aldrich Co., St Louis, MO, USA), penicillin (20 U/mL) and streptomycin (20 µg/mL) (SigmaAldrich Co.) at 37°C in a humid atmosphere containing 5% CO 2 . The cells were sub-cultured every 5±2 days.
Colostral purified SIgA
Human colostrum SIgA was purified from a defatted colostrum pool by affinity chromatography on Cyanogen bromideactivated Sepharose-4B (CNBr-Sepharose-4B; Sigma-Aldrich Co.) bound with sheep anti-human α chain as proposed by March et al. 29 To ensure SIgA depletion, fractions eluted from the affinity chromatography column were pooled and passed five times through the same column. Bound SIgA was eluted from the column with 6N glycine-HCl buffer, pH 2.8. The purified preparations were restored to the initial volume. The concentration of SIgA was determined by simple radial immunodiffusion with a sheep anti-human α chain serum on agarose plates. 16 Total protein concentration was determined by Lowry Method. The purified SIgA preparation was also tested by immunoelectrophoresis with goat anti-human γ and µ chain antisera. Both IgG and IgM were undetectable in the preparation. The purified SIgA was 4.0 g/L adjusted to a concentration of 100 ng/mL. The aliquots were stored at -80°C and subsequently used for experiments.
Peg microsphere preparation
The microspheres were obtained from PEG 6000 using a modification 22 ,23 of a previously described protocol. 21 Briefly, 20 g of PEG 6000 was resuspended in 100 mL of a 2% sodium sulfate solution in phosphate-buffered saline (PBS) and incubated at 37°C for 45 minutes. After incubation, the PEG microspheres were diluted 3:1 in PBS and washed twice in PBS (centrifuged for 500× g, 5 minutes). The PEG microspheres were resuspended in PBS. The formation of the microspheres was thermally induced by subjecting the solution to 95°C for 5 minutes. For adsorption, the suspensions of PEG microspheres in PBS were incubated with SIgA (Sigma-Aldrich Co.; concentration 100 ng mL SIgA were fluorescently labeled overnight at room temperature with a solution of Dylight-488 (Pierce Biotechnology, Rockford, IL, USA; 10 µg mL -1 ) in dimethylformamide at a 100:1 molar ratio of PEG:Dylight. The samples were then analyzed by fluorescence microscopy.
characterization of the Peg microspheres by flow cytometry
Immunofluorescence staining was performed with phycoerythrin (PE; Sigma-Aldrich Co.) to compare the abilities of the PEG and polymethylmethacrylate microspheres (CaliBRITE; BD Biosciences, San Jose, CA, USA) to bind fluorescent markers. The PEG microspheres were incubated with 5 µL of PE (0.1 mg mL -1 ) for 30 minutes at 37°C. After the incubation, the PEG microspheres were washed twice in PBS containing BSA (5 mg mL
; centrifuged for 500× g, 10 minutes, 4°C). In all of the experiments, the PEG microspheres were analyzed by flow cytometry. The study was performed on a FACSCalibur (BD Biosciences). The PEG microspheres sizes were compared to those of the BD microspheres (6 µm CaliBRITE 3 Beads, BD Biosciences catalog number 340486) bound or unbound to phycoerythrin (PE). The fluorescence intensity of the PEG microspheres was expressed as the geometric mean fluorescence intensity, and the size was calculated according to the geometric mean of the forward scatter.
Immunofluorescence of adsorbed SIgA
The PEG microspheres with or without adsorbed SIgA were fluorescently labeled with a F(ab')2 fragment of anti-human IgA conjugated to fluorescein isothiocyanate (FITC) (SigmaAldrich Co.) for 30 minutes at 4°C. The microspheres were analyzed by flow cytometry in all experiments (FACSCalibur; BD Biosciences).
release of iga adsorbed in Peg (Pegiga) microspheres
After adsorption of the IgA (100 ng/mL) onto the PEG microspheres the preparation was resuspended in RPMI culture medium to verify the IgA release. The PEG-IgA microspheres were incubated for 2, 12, and 24 hours at 37°C with 5% CO 2 . After this period, the suspensions of PEG-IgA were centrifuged for 10 minutes at 160× g. The IgA release in supernatant was determined using the IgA human enzymelinked immunosorbent assay (Abcam, Cambridge, UK). Reaction rates were measured by absorbance plate-reading spectrophotometer with a 450 nm filter. The results were calculated according to the standard curve.
cell treatment
To explore cell viability (propidium iodide [PI] permeability test), apoptosis induction (annexin V staining), and intracellular calcium release (fluo3-acetoxymethyl staining), sub-confluent (80%) monolayers of MCF-7 cells were treated with a concentration of trypsin (Sigma-Aldrich Co.) adjusted for 5×10 6 cells/mL. Then, the trypsinized cells were pre-incubated for 24 hours with or without 50 µL of SIgA (100 ng/mL final concentration), 50 µL of PEG microspheres or 50 µL of SIgA adsorbed in PEG (PEG-IgA) microspheres (100 ng/mL final concentration). Next, the cells were diluted in RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma-Aldrich Co.), penicillin (20 U/mL), and streptomycin (20 µg/mL) (Sigma-Aldrich Co.) at 37°C for 24 hours in a humid atmosphere containing 5% CO 2 .
cellular viability
After 24 hours of treatment, the culture medium was removed, and the cells were washed twice with PBS. The viability test was performed using PI fluorescence assay. 30 Then, the cells were stained with 10 µL of PI (1 mg/mL), Triton X-100 (5.5%), and ethylenediamine tetraacetic acid (110 mM) and incubated for 10 minutes at room temperature. Unstained cells were used as controls. The fluorescence of the cells was analyzed by flow cytometry (FACSCalibur system). The percentage of viable cells was conversely proportional to the geometric mean fluorescence intensity of PI.
intracellular ca 2+ release determination
We analyzed fluorescence staining using a FACSCalibur system to assess intracellular Ca 2+ release in MCF-7 cells. Cells were loaded with the fluorescent radiometric calcium indicator fluo3-acetoxymethyl (Fluo3-AM; Sigma-Aldrich Co.). Cell suspensions were incubated with 5 µL of fluo3-acetoxymethyl (1 µg/mL) for 30 minutes at 37°C. After incubation, the MCF-7 cells were washed twice in PBS containing BSA (5 mg/mL; centrifuged for 160× g, 10 minutes, 4°C) and then analyzed by flow cytometry (FACSCalibur system). Fluo-3 was detected using a 530/30 nm filter for intracellular Ca
2+
. The rate of intracellular Ca 2+ release was expressed as the geometric mean fluorescence intensity of Fluo-3.
apoptosis assay
Annexin V staining was used to assess apoptosis. Untreated cells were used as negative controls, and cells treated with staurosporine (Sigma-Aldrich Co.), which was used to induce apoptosis, were used as positive controls according to Pundt 
statistical analysis
An analysis of variance (ANOVA) was used to evaluate cellular proliferation, culture supernatant calcium levels, and the intracellular calcium and apoptosis index of MCF-7 cells in the presence or absence of PEG microspheres with adsorbed SIgA. Statistical significance was considered when P,0.05. Figure 1A shows a fluorescence microscopy image of PEG microspheres produced in PBS. This result confirmed that our method produces microspheres that are easily separated in the suspension. The produced microspheres retained their spherical structure without deformation ( Figure 1A) . Fluorescence microscopy showed that PEG microspheres are able to adsorb SIgA, which is distributed throughout the PEG microsphere surface ( Figure 1B) . To confirm the binding of SIgA to the microspheres, we used an F(ab')2 fragment of anti-human IgA conjugated to FITC. Figure 2 shows the positive binding of SIgA on the PEG microsphere surface. Figure 3A compares the PEG microspheres, PEG microspheres with adsorbed SIgA, and BD microspheres (standard) in terms of fluorescence intensity. The PEG microspheres showed a lower geometric mean fluorescence intensity when compared with the BD microspheres. The PEG microspheres with adsorbed SIgA showed geometric mean fluorescence intensity values similar to those of the BD microspheres. The PEG microspheres with adsorbed SIgA were also similar in size to the standard microspheres ( Figure 3B and C) .
Results
The release of SIgA adsorbed in PEG microspheres during 24 hours is illustrated in Figure 4 . The SIgA release increased over time; after 24 hours, more than 90% (92.4 ng/mL) of the antibody had been released.
The viability of MCF-7 cells is shown in Figure 4 . The MCF-7 cells which were not stimulated had higher viability. The PEG microspheres did not alter cell viability. When the MCF-7 cells were incubated with SIgA, cell viability decreased. MCF-7 cells had a lower viability index when incubated with PEG microspheres with adsorbed SIgA (Figure 5 ). Figure 6 shows the rate of intracellular Ca 2+ release in MCF-7 cells as measured by Fluo-3 fluorescence intensity. MCF-7 cells had low spontaneous intracellular Ca 2+ release. When these cells were incubated with SIgA or PEG microspheres with adsorbed SIgA, they had increased intracellular Ca 2+ levels (Table 1) . Intracellular Ca 2+ release was higher in MCF-7 cells treated with PEG microspheres with adsorbed SIgA compared with cells treated with PEG microspheres.
To evaluate apoptosis induction in MCF-7 cells, cells were stained with annexin V and analyzed by flow cytometry (Figure 7) . The control MCF-7 cells showed low levels of apoptosis. When these cells were incubated with PEG, we observed an increase in necrotic cells. In the presence of SIgA, the percentage of apoptotic cells increased. The highest apoptosis index was observed when the cells were treated with PEG microspheres with adsorbed SIgA (Table 2 ). 
Discussion
The protective effects of breastfeeding on breast cancer risk have been difficult to study due to the high correlation with parity. 32, 33 Reproductive factors may induce permanent changes in the mammary gland epithelium or in the surrounding 34, 35 These tissue changes most likely make the breast more or less susceptible to carcinogenic factors. 34 Secretory immunity is of great importance as a natural barrier because SIgA forms the first line of defense against pathogens and other potentially harmful agents. In this study, we produced PEG microspheres with adsorbed colostral SIgA and used an in vitro model to demonstrate that this biomaterial showed antitumor activity against MCF-7 human breast cancer cells, as evidenced by the decreases in cell viability, intracellular calcium release, and apoptosis.
Microsphere-based polymeric substances can be employed as release delivery systems for drugs and therapeutic proteins. In this study, fluorescence microscopy and flow cytometry showed that the PEG microspheres had ellipsoid shapes and were easily separated from the suspension. Flow cytometric analysis indicated that the PEG microspheres had a size of approximately 5.1 µm. The adsorption of colostral SIgA enhanced the microsphere size to approximately 5.7 µm, suggesting that SIgA may bind at the same site as the marker. The adsorption of SIgA to PEG microspheres was confirmed using monoclonal anti-IgA antibody conjugated to FITC. These data are consistent with previous studies, which found that PEG microspheres changed in size or in their ability to bind to fluorescent substances after the adsorption of bioactive molecules. [22] [23] [24] [25] [26] When a drug or protein is administered using a carrier, the drug/protein clearance decreases (half-life increases), volume of distribution decreases, and the area under the time versus concentration curve increases. 36 The carrier also maintains the drug/protein for an adequate period until the drug or protein reaches its required site of action and then releases it in a controlled fashion. 19 Thus, several studies have demonstrated that PEG microspheres are able to extend the time of the relative bioavailability of the drug compared with that of the free drug and to potentiate the pharmacological action. [37] [38] [39] [40] In this study we verified that PEG-IgA microspheres had a release profile that was satisfactory in terms of concentration and time.
The functions of SIgA in antigen-specific immunity have been shown to contribute in novel ways to the regulation of innate immunity. 41 SIgA protects against a number of microorganisms by acting as an opsonin, which blocks bacterial adherence to epithelial cells, neutralizes toxins, and prevents viral infections, 5, 16 and by simultaneously limiting the damaging effects of tissue inflammation caused by other antibody types. 15 Here, the PI fluorescence assay 30, 42 was used to verify that colostral SIgA decreased the growth of human MCF-7 cells; this inhibition of cellular growth was more evident when the cells were treated with SIgA adsorbed to PEG microspheres. These data show that the PEG microspheres are able to modify the release of SIgA and suggest that colostral SIgA presents anti-tumor properties and that SIgA is an important component of human breast milk that may decrease the risk of breast cancer.
The mammary gland structure provides for rapid growth, development, and immunological protection through its production of milk. The dynamic remodeling of the branched epithelial structure of the mammary gland in response to physiological stimuli during the reproductive cycle, differentiation into a secretory organ at parturition, post-lactational involution, and ultimately, regression with age is critical for these processes. The deregulation of these stimuli drives the transition of a physiological mammary microenvironment into a tumor microenvironment, facilitating malignant transformation. 43 Cancer development and progression are characterized by dynamic changes in the expression and function of protein 44 or of their associated signaling pathways, leading to the malignant transformation of cells in the breast. 45 In this study, colostral SIgA stimulated the release of intracellular calcium by human MCF-7 cells. The highest intracellular calcium level was associated with the treatment of cells with SIgA adsorbed to PEG microspheres, suggesting that the PEG microspheres can modify the effect of SIgA on intracellular calcium release.
Intracellular calcium is responsible for controlling various cellular processes including proliferation, differentiation, and cell death. 46 Alterations in the intracellular Ca 2+ influx in human cells may cause cell damage that eventually culminates in the activation of cell death pathways. 25, 46 The excessive release of intracellular Ca 2+ has been associated with induction of apoptosis in human cells. 47, 48 In this study, the increase of intracellular calcium in MCF-7 cells in the presence of IgA or PEG-IgA microspheres also increased the apoptotic index, and high rates of apoptosis were found in MCF-7 cells treated with PEG microspheres with adsorbed SIgA. Studies have shown that cellular calcium overload, or perturbation of intracellular calcium compartmentalization, can cause cytotoxicity and trigger apoptosis. 49 Apoptosis can be induced by intracellular signals that result in mitochondrial dysfunction, such as DNA damage or changes in metabolic pathways. 50 Studies have also shown that breast milk contains a human milk complex of LALBA and oleic acid that induces apoptosis in tumor cells. 2, 51 This study is the first to demonstrate that colostral SIgA presents oncostatic activity and that its adsorption in a modified delivery system improves this anti-tumor activity. Additional studies should be conducted to understand the mechanisms involved in cell death through colostral SIgA release by a modified delivery system.
The balance between a protective secretory immune response and the degree to which breastfeeding promotes reduced breast cancer risk depends on breastfeeding duration, frequency, exclusivity, and other personal factors that can be regulated systematically by the immune status of the individual. SIgA adsorbed to PEG microspheres may be used as an alternative anticancer immune-based therapy.
Conclusion
In conclusion, these data suggest that colostral SIgA adsorbed to PEG microspheres has antitumor effects on human MCF-7 breast cancer cells and that the presence of large amounts of this protein in secreted human breast milk may provide protection against breast tumors in women who breastfed. In addition, the modified delivery of SIgA may represent a possible alternative therapy for breast cancer treatment.
